Abstract: The present invention relates to a method for producing extended-release potassium citrate tablet containing camauba wax, wherein the method comprises heating the potassium citrate-carnauba wax mixture to a temperature below the temperature at which carnauba wax liquefies. This invention simplifies the production of extended release potassium citrate wax-matrix tablet.

Abstract: The present invention relates to a high dose extended-release potassium citrate tablet containing carnauba wax, which contains a first portion of melt- or heat-granulated carnauba wax and potassium citrate; and a second portion of non-granulated potassium citrate. The high dose extended-release potassium citrate tablet of this invention has robust batch-to-batch dissolution and friability; and leads to improved production capacity and reduced production cost.

Abstract: The present invention relates to a high dose extended-release potassium citrate tablet containing carnauba wax, which contains a first portion of melt- or heat-granulated carnauba wax and potassium citrate; and a second portion of non-granulated potassium citrate. The high dose extended-release potassium citrate tablet of this invention has robust batch-to-batch dissolution and friability; and leads to improved production capacity and reduced production cost.

Abstract: The present invention relates to a method for producing extended-release potassium citrate tablet containing camauba wax, wherein the method comprises heating the potassium citrate-carnauba wax mixture to a temperature below the temperature at which carnauba wax liquefies. This invention simplifies the production of extended release potassium citrate wax-matrix tablet.

Abstract: An aqueous pharmaceutical suspension for oral administration of a drug, which suspension maintains its content uniformity for prolonged period.

Abstract: Calcium-fortified acidic beverages that are stable against calcium precipitation when stored for prolonged period at room temperature and elevated temperatures.

Abstract: A substantially taste masked liquid pharmaceutical composition containing a pharmaceutically effective amount of an unpleasant tasting drug dissolved or dispersed in an aqueous excipient base, said excipient base comprising polyvinyl pyrrolidone and/or copolyvidone, and high molecular weight polyethylene glycol.

Abstract: The present invention provides a powdered beverage mix, comprising i) flavor(s), ii) calcium hydroxide, iii) citric and/or malic acid and, iv) a sugar selected from sucrose, fructose, glucose, and combinations thereof, wherein the ratios of acid/sugar and sugar/calcium are selected such that the calcium in the powdered beverage mix dissolves rapidly with very minimal calcium sedimentation when stirred by hand for less than about 60 seconds.

Abstract: Calcium-fortified acidic beverages that are stable against calcium precipitation when stored for prolonged period at room temperature and elevated temperatures.

Abstract: The present invention provides a powdered beverage mix, comprising i) flavor(s), ii) calcium hydroxide, iii) citric and/or malic acid and, iv) a sugar selected from sucrose, fructose, glucose, and combinations thereof, wherein the ratios of acid/sugar and sugar/calcium are selected such that the calcium in the powdered beverage mix dissolves rapidly with very minimal calcium sedimentation when stirred by hand for less than about 60 seconds.

Abstract: The present invention relates to insect repellant compositions containing, based upon the total weight of the composition, from about 6 to about 30 percent by weight of insect repellant active material having functionality selected from ester, amide, urethane or combinations thereof; from about 5 to about 30 percent by weight of alcohol, and from about 1 to about 10 percent by weight of nonionic surfactant. The compositions of the invention exhibit reduced rates of degradation of the active material in solution and are less drying and irritating to sensitive skin.

Abstract: An aqueous pharmaceutical suspension for oral administration of a drug, which suspension maintains its content uniformity for prolonged period.

Abstract: A substantially taste masked liquid pharmaceutical composition containing a pharmaceutically effective amount of an unpleasant tasting drug dissolved or dispersed in an aqueous excipient base, said excipient base comprising polyvinyl pyrrolidone and/or copolyvidone, and high molecular weight polyethylene glycol.

Abstract: Fatty acid-based compositions which include at least one neutralized fatty acid, a phenol group-containing compound, and a photostable organic ultra-violet absorber are provided. Additionally, a method of preparing such compositions is provided. The method includes neutralizing at least one melted fatty acid; adding an alkanolamine, a phenol group-containing compound, and a photostable organic UV absorber to the neutralized melted fatty acid to form a pourable composition; and cooling the pourable composition.

Abstract: The present invention relates to insect repellant compositions containing, based upon the total weight of the composition, from about 6 to about 30 percent by weight of insect repellant active material having functionality selected from ester, amide, urethane or combinations thereof; from about 5 to about 30 percent by weight of alcohol, and from about 1 to about 10 percent by weight of nonionic surfactant. The compositions of the invention exhibit reduced rates of degradation of the active material in solution and are less drying and irritating to sensitive skin.

Abstract: Non-carboxylated sulfated polyanions have been successfully used to rapidly obtain and maintain stable single-cell suspension of BTI-TN5B1-4 cells, a cell line which has a high intrinsic capacity for the expression of recombinant protein, but which clumps severely in suspension reducing its effectiveness as a host for foreign protein production with the baculovirus expression vector system. The three most effective polyanions for inducing a single-cell suspension were dextran sulfate, polyvinyl sulfate, and pentosan sulfate. The cost of dextran sulfate treatment is low compared to heparin treatment, which required a 20-fold higher lever to induce single-cell suspension. More importantly, dextran sulfate does not block vital infection at MOI.gtoreq.1 whereas heparin is known to seriously inhibit infection.